Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.contributor.author | Barriga‑Moreno, Adriana P. | |
| dc.contributor.author | Lozano‑Sánchez, Marcela | |
| dc.contributor.author | Barón‑Álvarez, Rafael A. | |
| dc.contributor.author | Cordoba, Juan P. | |
| dc.contributor.author | Aroca‑Martínez, Gustavo | |
| dc.contributor.author | Dianda, Daniela | |
| dc.contributor.author | Gonzalez‑Torres, Henry | |
| dc.contributor.author | Musso, Carlos G. | |
| dc.date.accessioned | 2024-04-08T19:24:49Z | |
| dc.date.available | 2024-04-08T19:24:49Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Introduction: Coronavirus disease 2019 (COVID‑19) induces organic damage mainly through the patient’s immune overreaction. Hemoperfusion (HPF) can remove infl ammatory cytokines and can reduce the negative effects of cytokine storm in COVID‑19. We compared the mortality rate, infl ammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID‑19 treated with and without HPF with HA330 cartridge. Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID‑19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330. Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post‑HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group. Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID‑19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis. | eng |
| dc.format.mimetype | eng | |
| dc.identifier.citation | Barriga‑Moreno AP, Lozano‑Sanchez M, Barón‑Alvarez RA, Cordoba JP, Aroca‑Martinez G, Dianda D, et al. Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID‑19 Critical Patients Treated with Hemoperfusion. Indian J Nephrol 2024;34:56-8. doi: 10.4103/ijn.ijn_175_22 | eng |
| dc.identifier.doi | DOI: 10.4103/ijn.ijn_175_22 | |
| dc.identifier.issn | 09714065 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/14485 | |
| dc.language.iso | eng | eng |
| dc.publisher | Wolters Kluwer | eng |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Indian Journal of Nephrology - IJN | eng |
| dc.source | Vol. 34 No. 1, (2024) | |
| dc.subject | Acute kidney injury | eng |
| dc.subject | COVID‑19 | eng |
| dc.subject | Hemoperfusion | eng |
| dc.title | Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion | eng |
| dc.type.driver | info:eu-repo/semantics/article | spa |
| dc.type.spa | Artículo científico | spa |
| dcterms.references | Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‑19 in Wuhan, China: A retrospective cohort Study. Lancet 2020;395:1054‑62. | eng |
| dcterms.references | Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID‑19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846‑8. | eng |
| dcterms.references | Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi‑Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID‑19) pandemic. J Am Coll Cardiol 2020;75:2352‑71. | eng |
| dcterms.references | Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID‑19 in Wuhan, China. Clint Infect Dis 2020;71:762‑8. | eng |
| dcterms.references | Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID‑19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033‑4. | eng |
| dcterms.references | Pomarè‑Montin D, Ankawi G, Lorenzin A, Neri M, Caprara C, Ronco C. Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. Blood Purif 2018;46:187‑95. | eng |
| dcterms.references | Ankawi G, Fan W, Pomarè Montin D, Lorenzin A, Neri M, Caprara C, et al. A new series of sorbent devices for multiple clinical purposes: Current evidence and future directions. Blood Purif 2019;47:94‑100. | eng |
| dcterms.references | Rampino T, Gregorini M, Perotti L, Ferrari F, Pattonieri EF, Grignano MA, et al. Hemoperfusion with cytosorb as adjuvant therapy in critically ill patients with SARS‑CoV2 pneumonia. Blood Purif 2021;50:566‑71. | eng |
| dcterms.references | Huang Z, Wang SR, Su W, Liu JY. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial 2010;14:596‑602. | eng |
| dcterms.references | He Z, Lu H, Jian X, Li G, Xiao D, Meng Q, et al. The efficacy of resin hemoperfusion cartridge on inflammatory responses during adult cardiopulmonary bypass. Blood Purif 2021;1‑7. | eng |
| dcterms.references | Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‑infected pneumonia in Wuhan, China. JAMA 2020;323:1061‑9. | eng |
| dcterms.references | Ronco C, Bagshaw SM, Bellomo R, Clark WR, Husain‑Syed F, Kellum JA, et al. Extracorporeal blood purification and organ support in the critically ill patient during COVID‑19 pandemic: Expert review and recommendation. Blood Purif 2021;50:17‑27. | eng |
| dcterms.references | Ronco C, Reis T. Kidney involvement in COVID‑19 and rationale for extracorporeal therapies. Nat Rev Nephrol 2020;16:308‑10. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion | spa |